Evidence map›Paper›PMID 39450544›Full record

ArticleBJPsych open2024

Cost-utility analysis of adapted problem adaptation therapy for depression in mild-to-moderate dementia caused by Alzheimer's disease: PATHFINDER randomised controlled trial.

Monica Panca, Robert Howard, Elizabeth Cort, Charlotte Rawlinson, Rebecca L Gould, Martin Wiegand, Anne Marie Downey, Sube Banerjee, Chris Fox, Rowan Harwood and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BJPsych open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Monica PancaComprehensive Clinical Trials Unit, University College London, UK.ORCID https://orcid.org/0000-0002-4031-6478
Robert HowardDivision of Psychiatry, University College London, UK.
Elizabeth CortDivision of Psychiatry, University College London, UK.
Charlotte RawlinsonDivision of Psychiatry, University College London, UK.ORCID https://orcid.org/0009-0000-2042-0203
Rebecca L GouldDivision of Psychiatry, University College London, UK.
Martin WiegandDepartment of Statistical Science, University College London, UK.
Anne Marie DowneyPriment Clinical Trials Unit, University College London, UK.
Sube BanerjeeFaculty of Medicine and Health Sciences, University of Nottingham, UK.
Chris FoxCollege House, University of Exeter, UK.
Rowan HarwoodSchool of Health Sciences, University of Nottingham, UK.
Gill LivingstonDivision of Psychiatry, University College London, UK.ORCID https://orcid.org/0000-0001-6741-5516
Esme Moniz-CookFaculty of Health and Social Care, University of Hull, UK.
Gregor RussellBradford District Care NHS Foundation Trust, Shipley, UK.
Alan ThomasCampus for Ageing and Vitality, University of Newcastle, UK.
Philip WilkinsonDepartment of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.ORCID https://orcid.org/0000-0003-2642-0604
Nick FreemantleComprehensive Clinical Trials Unit, University College London, UK.
Rachael Maree HunterPriment Clinical Trials Unit, University College London, UK.ORCID https://orcid.org/0000-0002-7447-8934

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDepression is common in people with dementia, and negatively affects quality of life.

aimsThis paper aims to evaluate the cost-effectiveness of an intervention for depression in mild and moderate dementia caused by Alzheimer's disease over 12 months (PATHFINDER trial), from both the health and social care and societal perspectives.

methodA total of 336 participants were randomised to receive the adapted PATH intervention in addition to treatment as usual (TAU) (

resultsThe mean cost of the adapted PATH intervention was estimated at £1141 per PATHFINDER participant. From a health and social care perspective, the mean difference in costs between the adapted PATH and control arm at 12 months was -£74 (95% CI -£1942 to £1793), and from the societal perspective was -£671 (95% CI -£9144 to £7801). The mean difference in QALYs was 0.027 (95% CI -0.004 to 0.059). At £20 000 per QALY gained threshold, there were 74 and 68% probabilities of adapted PATH being cost-effective from the health and social care and societal perspective, respectively.

conclusionsThe addition of the adapted PATH intervention to TAU for people with dementia and depression generated cost savings alongside a higher quality of life compared with TAU alone; however, the improvements in costs and QALYs were not statistically significant.

Indexed as

cost-effectivenesscost-utilityDementiadepressionquality-adjusted life years

Identifiers

PMID39450544
PMCPMC11698147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.